Retatrutide, the new dual GLP-1 and GIP receptor agonist, is currently not yet widely obtainable in the United Kingdom . While evaluations are ongoing, authorized availability dates remain unknown. Those interested in understanding more should discuss their healthcare provider about future options and remain aware of further developments regardi… Read More